Healthcare Digital Twins
In silico partner for biomedical industries across discovery, safety and clinical development: generating clinical evidence before trials reach people
TRIALS WITH DIGITAL TWINS
Test treatments on virtual human populations where real-patient trials are high-risk, slow to recruit or ethically constrained
NEW EVIDENCE FOR CRITICAL DECISIONS
Generate decision-relevant evidence from real-world data, informed by the frameworks safety teams including ICH E14/S7B, CiPA, 3Rs
OUTCOMES-BASED ACCESS
Refine eligibility criteria using new computational biomarkers, enabling a more precise selection of patients for outcomes-based reimbursement
CONTROL R&D/ PRODUCT RISKS
Anticipate cardiac risk earlier, cut late-stage failures and strengthen the statistical power of your trials. Protect both your timelines and budget
Recognised & supported by:
ELEM's healthcare digital Twins help pharmaceutical companies evaluate drug performance across diverse populations, identifying patient and treatment risks early. Integrating Virtual Human Trials early in drug development reduces late-stage failures, enhances patient safety, and minimises reliance on animal testing.
CROs adopting ELEM technology develop stronger relationships with sponsors by offering innovative solutions to mitigate trial delays, provide greater confidence in inclusion and exclusion criteria and explain outliers. CROs additionally leverage Virtual Human Populations for effective trial protocols and faster trials.
Safety first. ELEM’s standardised, comparable and repeatable trials with Virtual Humans enable regulators to compare and validate studies independently, faster and at lower cost. This increases regulators’ capacity to process new treatments and accounts for patient groups with unmet needs or rare diseases.
ELEM Virtual Human Populations reflect multiple patient & therapeutic scenarios, providing early insights into product safety and effectiveness. Virtual trials for high-risk devices generate precise evidence and avoid invasive procedures. This reduces patients' risks and leads to positive outcomes for clinicians and companies.
Safely deploying ELEM healthcare digital twins in the clinic helps doctors gain insights into patient responses to treatments whilst increasing patient engagement with visual information. Informed clinical decisions enable HDOs to optimise workflows with efficient cost models for best patient outcomes.
What they say about us
Solutions
Hit-to-lead optimisation
Taking into account molecule properties, assay variability, base PK/PD and binding properties (PPB), ELEM V.HEART-Discovery platform helps our clients screen high volumes of molecules (HTS) up to 100x effective concentrations. Early in-human QT prolongation profiling of the molecule over an extended range, significantly reduces risk during drug development.
Paediatrics patient scenarios
Using real data from 15 patients, ELEM studied 10 different pacing scenarios for each patient, using its virtual human technology. This enables a MedTech to assess the efficacy of the therapies of their devices, generating the data to eventually support its filing. Additionally, from these digital twins, ELEM developed a synthetic population of 150 additional patients to fill gaps in the study.
Safety trial in Cardio oncology
ELEM V.HEART platform provided the client with a 5x matching virtual cardio-oncology cohort of 120 gender-balanced Virtual Patients. Predictive results delivered within days enabled the clinical team to prevent adverse events, avoid recruitment delays, and enhance trial protocols.
Effective targeting in respiratory
Based on 100 detailed human anatomies of the respiratory system, we create a virtual population of 5,000 representing a real population. Our client analysed and optimised drug delivery to the target area for maximum efficacy: with studies completed in days, ensuring the project timeline was met without delays
Take it from Discovery to Development
Avoid changing the study model between pipeline stages.
Simulate your promising compounds with V.HEART-Trials to get granular around different populations of virtual hearts.
Discard unsafe molecules
Simulate your promising compounds
Take full control of the target population
+50
EXPERTS
Developing our technology: renowned medical, academic, and healthcare specialists
30%
RISK REDUCTION
Reducing failure rates with advanced cardiac safety predictions
80%
COST SAVINGS
Reducing R&D expenses by identifying cardiac risks earlier
15K
STUDIES
Digital Twins studies
800
MILLION HOURS
Dedicated to scientific testing
+150
SCIENTIFIC PAPERS
Supporting our technology
Our technology is the result of an agile, multidisciplinary R&D process, rooted in collaboration with academic institutions, clinical partners and regulatory bodies.
Biosimulation engine
HPC simulations of organ function and treatment response
Advanced AI analysis
Accelerated insights generation and predictions at scale
Cloud-deployed
Web-based platform adaptable to different use cases
